Biolidics Ltd. (8YY) AI Stock Analysis

• Market Cap: S$133.48M
• Dividend Yield: N/A
• Average Volume (3M): 412.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SG
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 1,733,441,800
• 10 Day Avg. Volume: 410,990
• 30 Day Avg. Volume: 412,950
• PEG Ratio: 0.50
• Price to Book (P/B): 16.43
• Price to Sales (P/S): 36.30
• P/FCF Ratio: -12.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: S$0.08 ▲(92.50% Upside)

The score is held back mainly by weak financial performance (persistent losses, negative ROE, and negative operating cash flow) despite strong revenue growth. Technicals are supportive with strong momentum above key moving averages, but overbought RSI raises near-term risk. Valuation remains pressured due to loss-making earnings and no dividend support.

Positive Factors

Revenue Growth

A 380.98% revenue surge signals strong market traction and product adoption, creating a durable top-line runway. Sustained revenue expansion can support scale, broaden customer relationships, and improve bargaining power with suppliers and partners if cost structure is brought under control.

Free Cash Flow Improvement

Improving free cash flow growth indicates the business is moving toward internal funding for operations and investment. Over months, consistent FCF growth reduces reliance on external capital, enhances liquidity flexibility, and supports reinvestment into R&D or commercialization initiatives.

Manageable Leverage

A debt-to-equity just above 1 suggests capital has been raised to finance growth without extreme overleverage. If coupled with improving revenues and FCF, this leverage can be a sustainable way to fund scaling and commercialization while preserving operational runway over the next several months.

Negative Factors

Profitability

Persistent negative net profit and EBIT margins with falling gross margin indicate structural cost or pricing pressure. Over a multi-month horizon, continued margin erosion undermines ability to convert revenue into sustainable earnings and hampers capacity to self-fund growth or absorb market shocks.

Operating Cash Flow

Negative operating cash flow means core operations are not generating cash to cover losses, forcing reliance on financing or equity raises. Persisting negative OCF over months raises liquidity and execution risk, constraining R&D, commercialization, and the ability to scale operations sustainably.

Return on Equity

A negative ROE reflects capital erosion and ineffective capital allocation. Over the medium term this reduces investor confidence and limits internal funding for growth, making the company more dependent on external capital and potentially diluting existing shareholders.

Biolidics Ltd. Business Overview & Revenue Model

Company Description

Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also provides laboratory services. The company was formerly known as Biolidics Limited and changed its name to Embracing Future Holdings Limited in June 2025. The company was incorporated in 2009 and is based in Singapore.

How the Company Makes Money

Biolidics generates revenue through multiple streams, primarily by selling its diagnostic products and services to hospitals, clinics, and laboratories. The company earns income from the direct sale of its proprietary cancer detection assays and related diagnostic kits, which are designed to improve the accuracy and efficiency of disease detection. Additionally, Biolidics may also engage in strategic partnerships with healthcare organizations, research institutions, and pharmaceutical companies to co-develop new diagnostic technologies, providing opportunities for licensing fees and collaborative research funding. The company may further enhance its revenue through government grants and subsidies aimed at supporting healthcare innovation, as well as potential international expansion into new markets where its products can address unmet medical needs.

Biolidics Ltd. Financial Statement Overview

Summary

Strong reported revenue growth, but profitability remains weak with negative net profit/EBIT margins and declining gross margin. Balance sheet is moderately leveraged (debt-to-equity slightly above 1) with negative ROE, and cash flow is mixed: improving free cash flow growth but still negative operating cash flow.

Income Statement

Biolidics Ltd. has shown a significant revenue growth rate of 380.98% in the latest year, indicating a strong recovery in sales. However, the company continues to face challenges with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased from previous years, reflecting potential cost management issues.

Balance Sheet

The company's debt-to-equity ratio is slightly above 1, indicating a balanced leverage position. However, the negative return on equity suggests that the company is not generating sufficient returns for its shareholders. The equity ratio is not provided, but the overall financial health appears to be strained by consistent losses.

Cash Flow

Biolidics Ltd. has shown a positive free cash flow growth rate, which is a positive indicator for liquidity. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is below 1, indicating that the company is not generating enough cash from its operations to cover its net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.77M	784.00K	277.00K	2.49M	2.31M	9.27M
Gross Profit	490.00K	187.00K	146.00K	1.16M	483.00K	3.80M
EBITDA	-1.00M	-3.03M	-1.16M	-8.50M	-4.58M	-3.52M
Net Income	-1.04M	-3.43M	-2.49M	-9.37M	-5.98M	-4.65M
Balance Sheet
Total Assets	4.80M	4.67M	682.00K	6.09M	11.42M	18.76M
Cash, Cash Equivalents and Short-Term Investments	300.00K	295.00K	183.00K	5.03M	3.96M	10.67M
Total Debt	2.52M	1.75M	2.02M	3.01M	4.25M	5.28M
Total Liabilities	3.69M	2.94M	2.67M	7.78M	9.09M	10.48M
Stockholders Equity	1.11M	1.73M	-1.99M	-1.69M	2.33M	8.27M
Cash Flow
Free Cash Flow	-2.69M	-2.32M	-1.97M	-3.16M	-5.20M	-2.76M
Operating Cash Flow	-2.68M	-2.31M	-1.97M	-3.06M	-4.64M	-2.43M
Investing Cash Flow	-5.00K	-5.00K	-2.69M	5.00K	-860.00K	-539.43K
Financing Cash Flow	2.83M	2.36M	-200.00K	4.18M	-1.15M	7.50M

Biolidics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8YY, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.05, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 66.59 is Neutral, neither overbought nor oversold. The STOCH value of 20.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:8YY.

Biolidics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1B1	67 Neutral	S$58.45M	6.46	47.36%	3.37%	1.58%	115.29%
569	58 Neutral	S$47.02M	-20.00	-3.23%	―	13.07%	-70.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8YY	49 Neutral	S$133.48M	-18.33	―	―	―	―
42C	43 Neutral	S$176.52M	-15.86	-431.07%	―	30.34%	17.14%

Biolidics Ltd. Corporate Events

Embracing Future Holdings Achieves NPAT Target, Releases Earn-Out Shares

Embracing Future Holdings Limited announced the successful achievement of the NPAT target by its subsidiary, Shenzhen Xiaozhao Network Technology Co., Ltd., for the earn-out period ending October 2025. The company exceeded its target by 154.7%, resulting in the release of 135,600,000 Earn-Out Consideration Shares to the vendor’s nominees, highlighting a significant milestone in its acquisition strategy.

The most recent analyst rating on (SG:8YY) stock is a Hold with a S$0.03 price target. To see the full list of analyst forecasts on Biolidics Ltd. stock, see the SG:8YY Stock Forecast page.